AAAhmad Alsaadi

Ahmad Alsaadi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ahmad Alsaadi has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Severe non-cardiogenic pulmonary edema following low-dose amlodipine ingestion: a case report

    by Fares Abboud, Mustafa Zain, Ahmad Alsaadi, Ghassan Bayat, Muhanad Maaita

    Introduction and Importance: Amlodipine, a dihydropyridine calcium channel blocker, is widely used for hypertension. While peripheral edema is common, non-cardiogenic pulmonary edema (NCPE) is rare and typically linked to overdose. This case reports severe NCPE at a low therapeutic dose. Case Presentation: A 40-year-old male with newly diagnosed hypertension, treated with amlodipine 5 mg and valsartan 160 mg daily for 4 days, was presented with severe sudden dyspnea, palpitations, and restlessness. Examination revealed bilateral lung crackles, oxygen saturation of 68%, and a respiratory rate of 38 breaths/min. Imaging and a pulmonary capillary wedge pressure of 8 mmHg confirmed NCPE. Amlodipine was discontinued, and hydrochlorothiazide 12.5 mg daily was initiated, leading to rapid improvement. Three months later, symptoms recurred 7 hours after accidental ingestion of two 5 mg amlodipine tablets, resolving upon cessation. Clinical Discussion: This is the first reported case of severe NCPE associated with low-dose amlodipine, confirmed by low wedge pressure and normal echocardiography. Recurrence after re-exposure suggests a possible association, though causality remains unconfirmed. Conclusion: This case highlights a potential rare association between low-dose amlodipine and severe NCPE, warranting further investigation. Clinicians should consider amlodipine in unexplained NCPE cases, with early discontinuation to improve outcomes.


  • Open Access

    A case report of a multivessel coronary vasospasm that responded to IV diazepam

    by Fares Abboud, Mustafa Zain, Ahmad Alsaadi, Farah Haneyah, Amal Jama, Ghassan Bayat

    Rationale: Coronary artery vasospasm (CAVS) is a significant cause of acute chest syndrome, often mimicking coronary artery disease on angiography, which may lead to unnecessary interventions like percutaneous coronary intervention or coronary artery bypass grafting. This case report aims to highlight the potential therapeutic role of intravenous (IV) diazepam in managing multivessel CAVS unresponsive to standard vasodilators, emphasizing the influence of psychological stress in such cases. Patient concerns: A 32-year-old male, a heavy smoker with a history of anxiety disorder and no familial coronary artery disease history, presented with angina. Diagnoses: Initial evaluations, including electrocardiogram, echocardiogram, and laboratory tests, were normal, but an exercise stress electrocardiogram was positive. Coronary angiography revealed severe lesions in the proximal left anterior descending and right coronary artery diagnosing multivessel CAVS. Interventions: The patient was unresponsive to intracoronary nitroglycerin and verapamil. During a panic attack in the procedure, 5 mg IV diazepam was administered. Outcomes: Treatment lead to symptom resolution and normal coronary arteries on repeat angiography, without plaques or stenosis. Lessons: This case demonstrates multivessel CAVS refractory to standard vasodilators but responsive to IV diazepam, as evidenced by angiographic resolution. The temporal association with a panic attack suggests a link to psychological stress, aligning with literature on stress-related cardiovascular events. Limitations include the single-case design, lack of provocation testing, and inability to definitively establish causality between anxiety and vasospasm, necessitating larger studies to confirm IV diazepam’s efficacy. Multivessel CAVS may respond to IV diazepam when standard treatments fail, particularly in cases associated with psychological stress. This case underscores the need for further research to validate the therapeutic potential of IV benzodiazepines in managing CAVS and to explore the interplay between psychological stress and cardiovascular events.


  • Open Access

    Investigating soluble CD40 ligand as a prognostic factor among acute coronary syndromes patients: A multi-center prospective case-control study

    by Reham Nofal, Nafiza Martini, Majd Hanna, Imad-Addin Almasri, Ahmad Rasheed Alsaadi, Tahani Ali

    Soluble CD40 ligand (sCD40L) is a protein that plays a crucial role in the inflammatory response associated with the development and progression of acute coronary syndrome (ACS). Recent studies have suggested that sCD40L may be a useful prognostic factor for ACS, but the data are conflicting. This study aimed to investigate the potential of sCD40L as a prognostic marker among ACS patients and provide valuable insights for clinical practice. To our knowledge, this is the first study of its type in the Arabic World. A multi-center prospective case-control study was conducted in Damascus, Syria, involving 158 participants with different ACS subtypes (STEMI, NSTEMI, UA) and a control group of healthy individuals. Sociodemographic data, medical history, and sCD40L levels were collected. The predictive ability of sCD40L for ACS, STEMI, NSTEMI, and UA was assessed using receiver operating characteristic (ROC) curves. Statistical analysis was performed using IBM SPSS version 25. The study included 58 STEMI, 33 NSTEMI, 36 UA patients, and 30 healthy individuals. The mean age of participants was 55 years (SD 10.7 years). Analysis of sCD40L levels revealed significantly higher concentrations in ACS patients compared to the control group (P < .001). ROC curve analysis demonstrated that sCD40L had a significant predictive ability for ACS, STEMI, and NSTEMI (P < .05), while its predictive value for UA was not statistically significant. This study provides evidence supporting the potential of sCD40L as a prognostic factor in ACS. The elevated levels of sCD40L observed in these subtypes indicate its potential usefulness in risk stratification and predicting adverse cardiovascular events. Further investigations are warranted to establish standardized sCD40L cutoff values and evaluate its clinical implications in the management of ACS patients.